^
    Back
    Association details:
    Biomarker:ER positive
    Cancer:HER2 Negative Breast Cancer
    Drug:AiTan (rivoceranib) (VEGFR-2 inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: C2 – Inclusion Criteria
    Source:
    clinicaltrials.gov
    Title:

    Apatinib With CDK4/6 Inhibitor and Endocrine Therapy in HR+/ HER2- Advanced Breast Cancer

    Excerpt:
    ...- Histologically confirmed HR + / HER2- invasive breast cancer (specific definition: immunohistochemical detection of ER> 10% tumor cell positive is defined as ER positive, PR> 10% tumor cell positive is defined as PR positive, ER and / or PR Positive is defined as HR positive; HER2 0-1 + or HER2 is ++ but negative followed by FISH detection,...
    Trial ID:
    BCTOP-L-M04
    Evidence Level:
    Sensitive: C2 – Inclusion Criteria
    Source:
    clinicaltrials.gov
    Title:

    A Randomized, Controlled, Open-label Clinical Trial of Adjuvant Intensive Therapy for HR+/ HER2-SNF4 Early Breast Cancer

    Excerpt:
    ...Histologically confirmed HR+/HER2- invasive breast cancer (defined by immunohistochemical detection of ER > 10% positive tumor cells were defined as ER positive, PR > 10% positive tumor cells were defined as positive PR, and ER and/or PR were defined as positive HR....
    Trial ID:
    NCT05889871
    More C2 evidence
    Evidence Level:
    Sensitive: C2 – Inclusion Criteria
    Source:
    clinicaltrialsregister.eu
    Title:

    Fulvestrant combined with apatinib in patients with hormone receptor-positive, HER-2 negative advanced breast cancer: a phase 2, single-arm, prospective study

    Excerpt:
    ...Histologically diagnosis of hormone receptor positive (ER and/or PR+), HER2 negative breast cancer(ER positive: immunohistochemistry (IHC) ＞1% tumor cell staining; PR positive: immunohistochemistry (IHC) ＞1% tumor cell staining; HER-2 negative: immunohistochemistry 0, 1+, or 2+ while FISH/CISH negative); 3. ...
    Trial ID:
    ChiCTR1900021617
    Less C2 evidence
    Evidence Level:
    Sensitive: C3 – Early Trials
    Source:
    Cancer Biol Ther
    Title:

    Phase II study of apatinib plus exemestane in estrogen receptor-positive, human epidermal growth factor receptor 2-negative metastatic breast cancer

    Published date:
    10/13/2023
    Excerpt:
    The median PFS (mPFS) and OS were 5.6 (95%CI: 4.3–6.9) months and 15.7 (95% CI: 9.7–21.7) months, respectively. The ORR, DCR, and CBR were 21.4%, 71.4%, and 46.4%, respectively….Apatinib plus exemestane exhibited objective efficacy in patients with ER+/HER2- MBC who have failed multiple lines of treatment.
    Secondary therapy:
    exemestane
    DOI:
    https://doi.org/10.1080/15384047.2023.2265055